Optimal choice of ionic and nonionic iron drugs for the treatment of iron deficiency anemia in pregnancy
Keywords:iron deficiency anemia, pregnant, ionic and nonionic iron preparations, maltofer
The article devoted to current problems of the iron deficiency anemia (IDA) treatment. Basic mechanisms and stages of this disease development are described. Based on the literature data a comparative analysis of the efficacy and safety of ferrotherapy with ionic and non-ionic iron drugs is perfumed, which include hydroxide polymaltose complex of ferric iron drugs. The main features of the treatment of iron deficiency anemia are showed.
Hepcidin is a major regulatory peptide which charges the homeostasis of the iron in the body. Scientific search continues, and soon we have a deeper understanding of his approach the frameworks.
In the treatment of iron deficiency anemia in pregnant and mothers should be observed principles of individualized approach for the high-iron drug use, giving a pronounced clinical effect with low probability of side effects. Good prospects for treatment of iron deficiency anemia in women have drugs that are based on the hydroxide polymaltose complex. IDA treatment should last not only to normalize the peripheral blood, but also to the reduction of iron in the tissues (depot).
Where possible, concomitant of iron It should be carried out after eliminate the cause of IDA.
Hydroxide polymaltose iron complexes is accompanied by minimal side effects, which greatly improves treatment compliance: strict observance of patients intended therapy of iron deficiency program, the implementation of the full scope of assignments and deadlines IDA treatment improves the quality of patients life and accelerate their recovery.
The first stage of treatment with oral iron agents should continue until the full restoration of hemoglobin level, red blood cell count, hematocrit and lasts 1.5-2 months. The next stage is the saturation of the iron depots, lasts 2-3 months. After saturation of depot iron dose need to reduce to 30-60 mg/day.
Criterion of treatment effectiveness with iron drugs is the reticulocytosis appearance in the peripheral blood after 5-7 day from the beginning of the first treatment. Indirect evidence for the effective treatment of iron supplementation is increase hemoglobin concentrations every day for 1 g/l.
How to Cite
Copyright (c) 2016 С. В. Видиборець
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.